Additionally, Agdashian et al. [102] noted that tremelimumab treatment can stimulate the activation of tumor-specific T cells, decrease T-cell clonality, and enhance the infiltration of CD3+ CD8+ T cells into the tumor, leading to noteworthy clinical and immunological outcomes in patients with HCC. Here, CD8A is linked to neoplasm.